Premium Insights | BiopharmaTrend

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed... Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million …

Continue ›››

Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after …

Continue ›››

The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a …

Continue ›››

The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?

An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting …

Continue ›››

What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra. OpenAI president, Greg …

Continue ›››

Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms

Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …

Continue ›››

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent. Everyone is talking about how Anthropic AI lab now designs drugs, hires the AlphaFold Nobel laureate, and ships Claude Science alongside Claude Code. …

Continue ›››

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO: several companies to watch in techbio space. …

Continue ›››

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune rejuvenation.

Continue ›››

Everyone is Launching AI Agents. What's Being Deployed?

A deep dive on the next cycle of biopharma's AI buildout Last year's "growing buzz around AI agents" that we surveyed has since grown into a full avalanche of infrastructure …

Continue ›››

Simulating the Control Arm: Virtual Patients at the Trial Bottleneck

Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap. Clinical trials remain the most expensive bottleneck in drug development. And although …

Continue ›››

From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Cancer AI has moved into some unusual territory. In one recent example, researchers at Linköping University reported that a 32-sensor electronic nose could distinguish ovarian cancer in blood plasma in …

Continue ›››